Resalis Therapeutics presented preclinical data at TIDES showing an antisense oligonucleotide (ASO) that targets miR‑22, a microRNA implicated in metabolic regulation, produced durable weight‑loss and favorable metabolic effects in animal models. Company executives argued the ASO acts on fat production and metabolism rather than appetite suppression, positioning it as a different therapeutic approach to GLP‑1 receptor agonists. Resalis framed the ASO as addressing long‑term weight maintenance and tissue effects where peptide drugs show limitations. The data are preclinical and company representatives emphasized next steps toward IND‑enabling studies.